Medicilon/MPI Preclinical Research Shanghai Introduces Board of Directors.MATTAWAN, Mich. -- Medicilon/MPI Preclinical Research Shanghai has announced its newly formed Board of Directors, which has equal representation from the two parent companies. The four directors include executives William U. Parfet and William Harrison from MPI MPI - Message Passing Interface Research, and Drs. Chun-Lin Chen and Jintao Zhang from Medicilon.
William U. Parfet, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of MPI Research, has over 30 years of experience in the pharmaceutical and biotechnology industries. After serving 20 years with The Upjohn Company, Mr. Parfet was President and CEO of Richard-Allen Medical before co-founding MPI Research in 1995. Mr. Parfet received his MBA MBA
Master of Business Administration
Noun 1. MBA - a master's degree in business
Master in Business, Master in Business Administration from the University of Michigan (body, education) University of Michigan - A large cosmopolitan university in the Midwest USA. Over 50000 students are enrolled at the University of Michigan's three campuses. The students come from 50 states and over 100 foreign countries. . Mr. Parfet will serve as Chairman of the Medicilon/MPI Preclinical Research Shanghai Board of Directors.
William Harrison, President and COO of MPI Research, has over 20 years of experience with contract laboratories. Mr. Harrison has been with MPI Research since it was founded. Prior to joining MPI Research, he was the Director of Regulatory Affairs and Operations at Pharmaco LSR 1. (networking) LSR - Label Switching Router.
2. (operating system) LSR - Local Shared Resources. . Mr. Harrison holds a BS in Biomedical Engineering Biomedical engineering
An interdisciplinary field in which the principles, laws, and techniques of engineering, physics, chemistry, and other physical sciences are applied to facilitate progress in medicine, biology, and other life sciences. from the New Jersey Institute of Technology.
Chun-Lin Chen, PhD, co-founder of Medicilon, Inc. and Shanghai Medicilon, will serve as the CEO of Medicilon/MPI Preclinical Research Shanghai. Dr. Chen received his PhD from Oklahoma State University Oklahoma State University, at Stillwater; land-grant and state supported; coeducational; chartered 1890, opened 1891 as Oklahoma Agricultural and Mechanical College, renamed 1957. , and completed postdoctoral training in the United States. Dr. Chen has held numerous leadership positions in professional scientific trade organizations in China, as well as other parts of the world.
Jintao Zhang, PhD, co-founder and CEO of Shanghai Medicilon, received his PhD from Shanghai Institute of Organic Chemistry and has served in a number of academic and private research institutions in China and the United States.
"The Board of Directors for Medicilon/MPI Preclinical Research Shanghai looks forward to creating a strong preclinical research presence in the Asian market," says board Chairman William Parfet.
"Pharmaceutical and biotechnology companies around the world will benefit from being able to conduct research cost-effectively in China according to US FDA FDA
Food and Drug Administration
n.pr See Food and Drug Administration.
n.pr the abbreviation for the Food and Drug Administration. standards, and market these products worldwide," adds the CEO and board member for Medicilon/MPI Preclinical Research Shanghai, Dr. Chun-Lin Chen.
The joint venture, announced on December 19, 2007, will be located at the Chuansa Science Park in Shanghai, China and will offer customers of both companies the ability to conduct preclinical research at an Eastern facility that meets regulatory expectations across the globe, including the US FDA.
For further information, please visit www.medicilon-mpi.com.